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Abstract
Background: Staphylococcus aureus is one of the most important human pathogens and methicillin-resistant variants
(MRSAs) are a major cause of hospital and community-acquired infection. We aimed to map the geographic distribution of
the dominant clones that cause invasive infections in Europe.
Methods and Findings: In each country, staphylococcal reference laboratories secured the participation of a sufficient
number of hospital laboratories to achieve national geo-demographic representation. Participating laboratories collected
successive methicillin-susceptible (MSSA) and MRSA isolates from patients with invasive S. aureus infection using an agreed
protocol. All isolates were sent to the respective national reference laboratories and characterised by quality-controlled
sequence typing of the variable region of the staphylococcal spa gene (spa typing), and data were uploaded to a central
database. Relevant genetic and phenotypic information was assembled for interactive interrogation by a purpose-built
Web-based mapping application. Between September 2006 and February 2007, 357 laboratories serving 450 hospitals in 26
countries collected 2,890 MSSA and MRSA isolates from patients with invasive S. aureus infection. A wide geographical
distribution of spa types was found with some prevalent in all European countries. MSSA were more diverse than MRSA.
Genetic diversity of MRSA differed considerably between countries with dominant MRSA spa types forming distinctive
geographical clusters. We provide evidence that a network approach consisting of decentralised typing and visualisation of
aggregated data using an interactive mapping tool can provide important information on the dynamics of MRSA
populations such as early signalling of emerging strains, cross border spread, and importation by travel.
Conclusions: In contrast to MSSA, MRSA spa types have a predominantly regional distribution in Europe. This finding is
indicative of the selection and spread of a limited number of clones within health care networks, suggesting that control
efforts aimed at interrupting the spread within and between health care institutions may not only be feasible but ultimately
successful and should therefore be strongly encouraged.
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Introduction
Staphylococcus aureus is the main cause of purulent infection
in humans [1]. S. aureus has the potential for local as well as
disseminated infection and can cause lesions in all tissues and
anatomical sites. Infections can be either acquired in the
community or in association with health care. The position of
S. aureus as one of the most important human pathogens is largely
due to its virulence potential and ubiquitous occurrence as a
coloniser in humans, domestic animals, and livestock [2]. Between
25% and 35% of healthy human individuals carry
S. aureus on the skin or mucous membranes [3]. Any injury that
compromises epithelial integrity, trauma, medical or surgical
interventions, as well as viral infections, can lead to tissue invasion
[4–6]. It is assumed that severity and outcome depend largely on
the virulence of the introduced strain and the immune repertoire
of the host [7,8]. Occasionally, S. aureus acquires enhanced
virulence and antimicrobial resistance through horizontal DNA
transfer and maintains these mobile genetic elements in a
predominantly clonal genomic background. Thus, clones of S.
aureus are relatively stable and mainly diversify by the accumula-
tion of single nucleotide substitutions in the absence of frequent
interstrain recombination. It is therefore possible to discern
different clones and clonal lineages by molecular typing [9]. This
method allows several important observations to be made
regarding the evolution, epidemiology, and spread of clones with
particular public health importance, such as hospital-, community-
, and livestock-associated methicillin-resistant S. aureus (MRSA).
For MRSA, this surveillance is particularly important because it
appears that certain clones have disseminated over wide
geographical regions and are threatening major improvements in
curative and public health medicine [10]. A geographically
detailed description of this expansion on a continent-wide scale
has been inadequate, however, due to the lack of appropriate
surveys and agreement on a consistent application of standardized
molecular typing approaches. At the same time, little is known
about the population structure and geographical abundance of
methicillin-susceptible S. aureus (MSSA), which provides the
genetic reservoir from which MRSA emerge.
The present study was designed to fill these knowledge gaps and
to provide (i) the first representative and contemporaneous
snapshot of the genetic population structure of S. aureus (based
on spa typing) that cause invasive infection in the European region;
(ii) insights into the geographic distribution of different clones
among MSSA and MRSA on a continent-wide scale; and (iii) a
public Web-based mapping tool supplying interactive access and
an intuitive illustration of the results generated by this large-scale
typing initiative. The current study was also set up to establish the
logistics for future collaborative studies that will continue to
improve crucial knowledge for clinicians and diagnostic laborato-
ries about the geographic and temporal dynamics of the MSSA/
MRSA clones and their epidemic patterns in neighbouring
geographical areas. Lastly, the study is intended to additionally
strengthen the role of the S. aureus Reference Laboratories (SRLs)
by exposing and communicating potentially important public
health threats to health professionals and the general public.
Methods
spa Typing
Epidemiological typing uses highly discriminatory genetic
markers that characterize human pathogens allowing the identi-
fication of isolates that are closely related due to recent common
ancestry. The spa locus of S. aureus codes for protein A, a species-
specific gene product known for its IgG binding capacity. This
locus is highly polymorphic due to an internal variable region of
short tandem repeats, which vary not only in numbers but also
because of nucleotide substitutions within individual repeat units
[11]. DNA sequences of the spa gene therefore provide portable,
unambiguous, and biologically meaningful molecular typing data,
which have demonstrated their utility for epidemiological purposes
such as transmission and outbreak investigations at various
geographical levels [12,13].
Capacity Building
During three workshops organised for technical personnel from
28 European SRLs, participants received hands-on training in spa
sequence typing and spa sequence analysis according to a standard
protocol using a purpose-designed software tool, StaphType,
developed by Ridom GmbH [13]. Proficiency testing was carried
out by mailing each SRL five well-characterized S. aureus isolates
and five sequence chromatograms (trace files) of known spa types
as described previously [14,15]. All laboratories participating in
the structured survey described here fulfilled quantifiable quality
criteria, which consisted of an unambiguous base-calling of all
sequenced nucleotides for both forward and reverse sequencing
runs of the test panel.
Structured Survey
A protocol was drawn up and circulated for comment to all
SRLs and agreed upon in April 2006. Following this protocol,
European SRLs were asked to identify approximately 20
laboratories that serve hospitals and that are geographically and
demographically representative of their country, and secure their
participation. These laboratories were chosen from those that
regularly participate in the European Antimicrobial Resistance
Surveillance System (EARSS). For 6 mo, from September 2006
until February 2007, these participants were asked to submit the
first five successive MSSA isolates and the first five successive
MRSA isolates from individual patients with invasive infection. An
invasive infection was defined as a localised or systemic
inflammatory response to the presence of S. aureus at otherwise
sterile anatomical sites. Isolates were dispatched by the partici-
pating laboratories to the SRLs accompanied by additional
information, including the EARSS laboratory identifier, the
sample number, the date of isolation, origin of clinical specimen,
demographic detail (such as age and gender), epidemiological
context (hospital-acquired when symptoms developed more than
48 h after admission or as community-onset otherwise), isoxazo-
lylpenicillin- (i.e., oxacillin) or cefoxitin-resistance, and all-cause
mortality 14 d after isolation of the first invasive isolate. SRLs
confirmed MRSA by mecA PCR or determination of minimum
inhibitory concentration for oxacillin together with PBP2a
agglutination. Additional data were uploaded to the database
and Web application if available. These consisted of staphylococ-
cal cassette chromosome mec (SCCmec) typing, and identification of
luk-PV genes, indicative of Panton-Valentine Leukocidin (PVL).
All SRLs preserved the isolates in strain collections and performed
spa sequence typing according to the standard protocol, uploaded
the sequence information, and made this available by synchroni-
sation with the central Ridom SpaServer (www.spaserver.ridom.
de) curated by SeqNet.org at the Institute of Hygiene, University
Hospital Mu¨nster, Germany [15,16]. Submitted sequences were
quality controlled by comparison with accompanying chromato-
grams (trace files) and excluded if stringent quality criteria for
excellent sequencing data were not fulfilled. spa types were
grouped into spa complexes if a single genetic event such as single
insertions, single deletions, or single nucleotide polymorphism
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could account for the observed sequence divergence. In the
following the designation of spa types indicated by lower case ‘‘t’’
follow the nomenclature used by the spa server and multilocus
sequence types are reported as sequence type (ST) according to
convention [17]. Finally, the SCCmec type is also added to a string
consisting of spa type/ST/SCCmec all in parenthesis, e.g., (t032/
ST22/SCCmecIV).
Epidemiological and typing data were communicated in parallel
to a central SQL database at the National Institute for Public
Health and the Environment (RIVM) of the Netherlands. For each
participating laboratory, SRLs also provided the postal address
and indicated their administrative region (such as region, province,
state, department, or NUTS-2 level) if the location of laboratories
were to be aggregated on a higher administrative geographical
level for display on the interactive mapping tool (which was done
only for Austria, Belgium, Czech Republic, and Poland). All data
were anonymous and collected in accordance with the European
Parliament and Council decision for the epidemiological surveil-
lance and control of communicable disease in the European
community [18,19]. Ethical approval and informed consent were
thus not required.
Data Analysis, Geographical Illustration, and Cluster
Identification
All data were inspected for inconsistencies and analysed on a
country-by-country basis and returned to SRLs for feedback,
clarification of inconsistencies and final approval in February 2008.
After final approval, data were analysed using Stata version 10 and
SAS version 9.1 (SAS Institute Inc.) using chi-square test for
proportions and Student’s t-test for continuous variables. The index
of diversity is an unbiased measure of the probability of drawing two
different spa types given the distribution of spa types in the sample.
The 95% confidence intervals (CIs) were calculated as described
previously [20]. Postal address and location of all sampling
laboratories were converted into decimal cartesian coordinates
using the geocoding facility at www.spatialepidemiology.net [21].
Pairwise distances of laboratories that isolated MSSA and MRSA
with identical spa types were calculated and distance matrices
were summarised and compared by nonparametric tests. The
Web application SRL-Maps (http://www.spatialepidemiology.net/
srl-maps) was developed to interrogate the data on the basis of
mapping of laboratory locations and on centroids of administrative
regions (when laboratory results were aggregated at the level of
administrative region).
A spatial scan statistic was used to identify the geographic
distribution of specific spa types at two levels: (i) country-specific
frequencies that take into account all spa types within national
boundaries and (ii) regional clusters of varying size independent of
national boundaries. To identify spa types with higher than
expected occurrence in any of the participating countries, the
observed number of all spa types isolated within each country was
compared with the number expected under the assumption of a
European-wide random distribution. For the identification of
regional clusters, circular windows around all laboratory locations
were projected. For each location, the radius of the window was
varied from 0 to 1,000 km. In this way, a finite number of distinct
windows was created. For each window, the observed number of
isolates with a specific spa type was compared with the expected
number under the assumption of a random distribution. 10,000
random distributions were obtained by varying the composition of
local spa types at all laboratory locations consistent with
cumulative spa-specific frequencies using Monte Carlo Simula-
tions. The test statistic was calculated by log-likelihood ratio test,
whereby countries or windows where the observed spa type
frequencies differed from those obtained by simulation were
considered to contain significant clusters with an alpha error of
p,0.0001. The scan-statistic was executed with SaTScan software
using SAS macros [22,23].
Results
Summary Statistics
26 SRLs from 26 countries satisfactorily fulfilled the proficiency
criteria for spa sequence typing and contributed data for final
analysis. Between September 2006 and February 2007, 357
laboratories serving 450 hospitals (Figure 1) collected 2,890
successive MSSA and MRSA isolates from patients with invasive
Figure 1. Locations of participating laboratories.
doi:10.1371/journal.pmed.1000215.g001
Geographic Distribution of S. aureus
PLoS Medicine | www.plosmedicine.org 3 January 2010 | Volume 7 | Issue 1 | e1000215
S. aureus infection (2,603 from blood cultures, 90.1%; 17 from
cerebrospinal fluid, 0.6%; and 270 from puncture fluids of other
normally sterile anatomical sites, 9.3%). Final inspection of data
revealed missing information for gender (28 isolates, 1%), age (54
isolates, 1.9%), sampling dates (74 isolates, 2.6%), epidemiological
context (community onset or hospital acquisition, 568 isolates
19.7%), all-cause mortality 14 d after S. aureus isolation (1052
isolates, 36.4%), and spa type (40 isolates, 1.4%). Table 1 gives a
summary overview of the number of participating laboratories,
isolates, and spa types submitted by country. Many laboratories
were unable to collect five invasive MRSA isolates within the
sampling period because of a low MRSA incidence in the hospitals
they serve. Therefore, the combined collection consisted of
two-thirds MSSA (1,923; 66.5%) and one-third MRSA (967;
33.5%, Table 2). Patients with invasive MRSA infections were
older (Figure 2) with a median age of 69 y compared to a median
age of 63 y in MSSA patients (p,0.001). Moreover, MRSA
patients had higher all-cause mortality (20.8%) 14 d after the first
isolation of S. aureus than MSSA patients (13.2%, p,0.0001). More
males (1,765/2,862; 61.7%) than females had invasive S. aureus
infections. The proportion of MRSA compared to MSSA did not
differ between the sexes (p=0.2). Of the 231 MRSA that were
reported as community-onset (CO-MRSA), 226 (97.8%) were
tested for the presence of PVL-associated genes luk-PV and ten
(4.4%) were positive. Of the 585 hospital-acquired MRSA (HA-
MRSA), 551 (94.2%) were tested for PVL and six (1.1%) were
positive. The difference was significant (p=0.009).
spa Typing
A total of 660 spa types were reported (Table 2). Among all spa
types, 565 and 155 were assigned to MSSA and MRSA,
respectively, of which, 505 were exclusively identified as MSSA
and 95 for MRSA alone. 60 spa types contained both MSSA and
MRSA. 27 of the MSSA (1.4%) and 13 of the MRSA (1.3%)
isolates were nontypeable. Table 3 shows the rank order of the
most frequent spa types isolated during the survey and Table 4 the
three most frequent spa types by country. MRSA was less diverse
than MSSA. Only five spa types accounted for almost half (48.1%)
of all MRSA isolates, whereas the same proportion of MSSA
isolates comprised the 26 most frequent MSSA spa types. Estimates
of the genetic diversity differed significantly with an index of
diversity for MSSA of 0.985 (95% CI 0.983–0.987) and 0.940
(95% CI 0.933–0.947) for MRSA. While MSSA diversity ranged
between 0.934 in Latvia and 1.0 in Iceland (unpublished data),
Table 1. Summary overview of participating laboratories, hospitals, number of invasive isolates of MSSA and MRSA, and spa types
by country.
Country n Labs n Hospitals n Isolates MSSA MRSAa n spa Types MSSA n spa Types MRSA n Not Typeable Percent Not Typed
Austria 18 48 174 120 54 70 19 1 0.6
Belgium 22 22 195 107 88 65 25 1 0.5
Bulgaria 8 8 54 29 25 23 11 0 0.0
Croatia 11 11 88 50 38 27 13 6 6.8
Cyprus 1 1 16 9 7 8 5 0 0.0
Czech Republic 20 20 145 94 51 64 9 0 0.0
Denmark 14 30 112 108 4 72 2 0 0.0
Finland 5 5 22 15 7 14 7 0 0.0
France 23 23 225 114 111 75 27 0 0.0
Germany 27 27 180 98 82 56 20 1 0.6
Greece 3 3 35 20 15 12 6 6 17.1
Hungary 10 13 110 66 44 35 9 2 1.8
Iceland 1 1 5 5 0 5 0 0 0.0
Ireland 22 22 169 85 84 55 26 0 0.0
Italy 19 19 147 80 67 53 15 0 0.0
Latvia 11 12 43 38 5 20 1 0 0.0
Malta 1 1 15 3 12 2 5 3 20.0
Netherlands 18 21 204 195 9 98 9 6 2.9
Norway 11 20 55 55 0 38 0 1 1.8
Poland 23 23 179 132 47 42 14 0 0.0
Portugal 12 12 88 48 40 36 13 0 0.0
Romania 10 10 36 25 11 18 3 0 0.0
Slovenia 11 12 58 48 10 29 3 2 3.4
Spain 21 21 204 113 91 58 19 1 0.9
Sweden 20 47 200 195 5 90 5 3 1.5
UK 15 18 131 71 60 51 18 7 5.3
Total 357 450 2,890 1,923 967 565 155 40 1.4
aThe number of MRSA isolates does not reflect a prevalence or occurrence in particular countries as the protocol requested submission of the first five MSSA and MRSA
isolates.
doi:10.1371/journal.pmed.1000215.t001
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MRSA diversity between countries was more heterogeneous
ranging from 0.62 in Romania to 0.91 in Austria (Figure 3),
indicating the presence of few dominant MRSA spa types in
several countries. Accordingly, MRSA showed a higher degree of
geographic clustering as the average distance between laboratories
that isolated the same spa type was significantly smaller than for
MSSA (Table 2). No correlation between genetic diversity of
MRSA and overall proportion of MRSA among S. aureus blood
stream infections at country level as reported to the EARSS
database for 2007 was found (r=20.09, p=0.75) [24], indicating
that single successful spa types cannot explain the variance in the
proportion of MRSA causing S. aureus blood stream infections
observed in Europe.
Clustering of spa Types at Country and Regional Level
In 17 countries, 22 spa types were found with frequencies that
were unexpected when applying the hypothesis of a random
distribution, indicative of local epidemics (Table 5). Most (86.9%)
of these were MRSA. In ten countries two spa types coexisted with
unexpected frequencies. In four of them, these two spa types
showed a close genetic relationship and belonged to the same spa
complex whereby a single genetic event could account for the
sequence divergence between the types. There was also a frequent
regional coincidence with neighbouring countries sharing identical
epidemic spa types. The Czech Republic and Germany shared spa
type t003 (t003/ST225/SCCmecII), Bulgaria and Romania shared
t030 (t030/ST239/SCCmecIII), the UK and Ireland t032 (t032/
ST22/SCCmecIV), Italy and Croatia shared t041 (t041/ST228/
SCCmecI), and strain t067 (t067/ST5125/SCCmecIV) whose
dominance in Spain was first identified through this initiative
[25], was also found in southern France. The notion of regional
spread was supported by the cluster statistic that projected
windows beyond national boundaries for this dataset (Table 6).
The degree of unexpectedness, which is an indication of the
significance of each cluster, is expressed by the log likelihood ratio
(LLR). The majority of regional clusters extended beyond national
boundaries and 74% of all isolates that occurred in these clusters
were MRSA. The most significant cluster was identified in Spain
and consisted of spa type t067 (t067/ST5&125/SCCmecIV). A
northern Balkan/Adriatic cluster consisting of spa type t041 (t041/
ST228/SCCmecI) was found in Austria, Hungary, Slovenia,
Croatia, and northern and central Italy. In Britain and Ireland,
t032 (t032/ST22/SCCmecIV), known as epidemic MRSA 15
(EMRSA-15), was the dominant type and represented the third
most significant cluster. An additional cluster of spa type t032,
albeit less significant and much smaller, was located in the
Brandenburg area of Germany. Central Germany, the Czech
Republic, and western Poland were included in a large regional
cluster of spa type t003 (t003/ST225/SCCmecII), which was
geographically centred in Saxony and had a radius of approx-
imately 400 km corresponding to the German hospitals partici-
pating in the study. Figure 4 provides a geographical illustration of
these clusters. The largest cluster in size as well as in numbers
(radius 930 km, 119 isolates) consisted of spa type t008 and was
centred in southern France. This cluster consisted of ST8 and
contained different subclones as it included both MSSA and
MRSA, and MRSA isolates exhibited two different SCCmec
elements (SCCmecI and IV). A smaller cluster, ranking in sixth
position in terms of significance, was located in Flanders on the
Belgian-Dutch border and consisted of spa type t740 (t740/ST45/
SCCmecIV). Interestingly, regional spa clusters with overlapping
geographical range were frequently made up of spa types that
belonged to the same spa complex, a clear indication that local
spread is accompanied by local evolution of the rapidly evolving
spa locus. Clusters with the smallest size (0 km) included those
submitted by single laboratories most likely reflecting single
hospital outbreaks. Three regional clusters consisted of MSSA
alone. They were located in Latvia (t435/ST425), Poland (t127/
ST1), and Denmark (t230/ST45), indicating that regional spread
of S. aureus is not limited to MRSA alone.
SRL-Maps
The Web application SRL-Maps (http://www.spatialepidemiology.
net/srl-maps) provides a community tool for the interrogation of the
geographic distribution of different spa types. All laboratory and
regional locations across Europe are represented as placemarks on
a Google map. Clicking on a placemark displays, below the map,
all spa types identified at that location (and their frequency)
along with the number of isolates (and number of geographic
locations) found elsewhere (if any) for each of these
Table 2. Summary statistics of S. aureus isolated in 26 European countries.
Statistics na MSSA MRSA Total/Overall p-Value*
Frequency (%) 2,890 1,923 (66.5) 967 (33.5) 2,890 (100%) —
Median age (IQR) 2,836 63 (46–75) 69 (55–78) 66 (49–76) ,0.0001
Male gender (%) 2,862 1,159 (60.8) 606 (63.3) 1,765 (61.7) 0.2
All-cause mortality after 14 d (%) 1,838 153 (13.2) 141(20.8) 294 (16.0) ,0.0001
Hospital acquisition (%) 2,322 777 (51.6) 585 (71.7) 1,362 (58.7) ,0.0001
N spa types 2,850 565 155 660b —
N not typeable 2,850 27 (1.4) 13 (1.3) 40 (1.4) 0.9
Index of diversity (95% CI) 2,850 0.985 (0.983–0.987) 0.940 (0.933–0.947) 0.983 (0.982–0.984) ,0.05c
Mean distance in kilometres between laboratories
that isolated identical spa types (95% CI)
1,614d 1,046.2 (1109.5–983.0) 786.8 (975.7–597.9) — 0.03d
*p-Value for the comparison of MSSA versus MRSA.
aNumber of isolates for which data were available.
bTotal number of spa types includes 60 spa types that contain both MSSA and MRSA.
cDeduced from non-overlapping 95% confidence intervals.
dIncludes only MRSA and MSSA with more than ten isolates per spa type.
IQR, interquartile range.
doi:10.1371/journal.pmed.1000215.t002
Geographic Distribution of S. aureus
PLoS Medicine | www.plosmedicine.org 5 January 2010 | Volume 7 | Issue 1 | e1000215
spa types (Figure 5). The European distribution of any spa type can
then be displayed and placemarks on the map are colour-coded on
the basis of whether the isolates at each location are all MSSA
(green), all MRSA (red), or are a mix of MSSA and MRSA
(yellow), with the number of isolates inside the placemark.
Graphical charts are displayed showing spa type-specific propor-
tion of MRSA/MSSA, all-cause mortality at 14 d, and the age
distribution among cases (Figure 5). This method allows the
identification and mapping of strains with particular public health
importance and further exploration by the scientific community is
encouraged.
Observations on Specific spa Types
For both MSSA and MRSA isolates, there was no association
between specific spa types and all-cause mortality after 14 d,
indicating that no spa type was associated with hyper-virulence. Of
the ten CO-MRSA isolates that were found to be PVL-positive,
three were assigned to spa type t044 (t044/ST80/SCCmecIV), the
so-called European community-acquired (CA)–MRSA, and an-
other three had spa type t008 (t008/ST8/SCCmecIV) and are
indistinguishable from USA300 CA-MRSA. Of the four other
PVL-positive CO-MRSA, two belonged to t622 (spa complex 8/
ST8/SCCmecIV), one to t529 (ST1043/SCCmecV), and one to
t437 (not further characterised). MRSA belonging to ST398 have
recently emerged in several European countries and are regarded
as being livestock-associated (LA-MRSA). Of all spa types typically
associated with this clone, spa types t011, t034, t571, t1255, and
t2383 were identified on 12 occasions (1.3%) in eight countries
during this survey. None of these isolates, however, displayed an
MRSA phenotype or harboured the mecA gene.
Figure 2. Age distribution and all-cause mortality of patients 14 d after diagnosis of invasive S. aureus infections in Europe. Age
divided in bands of 5 y, except for infants under 1 y (21).
doi:10.1371/journal.pmed.1000215.g002
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Discussion
Predominant spa types showed a wide geographic distribution.
The average distance between the locations from which the same
spa types were sampled was smaller for MRSA isolates than MSSA
isolates, suggesting a higher degree of geographical clustering of
MRSA. Moreover, genetic diversity was much lower for invasive
MRSA than MSSA and differed considerably between countries.
Spatial-scan statistics corroborated a fundamental difference
between MRSA and MSSA with respect to regional dissemination.
The majority of isolates that formed regional clusters were MRSA,
and 13 of the 15 major MRSA spa types (defined as more than ten
isolates in the database) occurred in geographical clusters. They
were typically hospital acquired and no more than three clusters
overlapped in the same region. Conversely, of the 27 major MSSA
spa types, only five showed significant geographical clustering and
only three consisted of MSSA alone. Thus, invasive MRSA clones
in Europe display a typical epidemic behaviour and have a
predominantly regional distribution. To unravel the dynamics of
spread of these epidemic MRSA requires the present type of
survey to be repeated every few years.
The emergence of MRSA occurs by the acquisition of the
methicillin resistance determinant (SSCmec) by MSSA strains.
MRSA strains typically emerge from the most prevalent MSSA
strains and it is a rare event, although new findings suggest that it
is more frequent than originally suggested [26,27]. There are thus
fewer MRSA clones compared to MSSA clones and they are very
young on evolutionary time scales (less than 50 y old) and have
had little time to diversify since they arose, whereas MSSA are
much older and thus more diverse. MRSA clones also expand
because of the selective forces exerted by heavy antibiotic use in
hospitals and conditions that favour transmission within and
between hospitals, which constrains their diversity. In contrast,
MSSA will be subject to much weaker selection leading to neutral
genetic drift that maintains their diversity. Geographic spread of
MRSA clones will be facilitated by repeated hospital admissions
and referrals of MRSA carriers [28] who typically belong to an
older and thus less mobile segment of the population. The broader
distribution of MSSA clones may reflect dissemination by hosts
with different travel patterns than MRSA carriers as well as the
longer time that MSSA clones have had to spread.
The present survey set several precedents in the field of
molecular epidemiology of S. aureus. First, it brought together
reference laboratories from 26 European countries adopting a
standardised quality-controlled DNA sequence-based typing
method; second, it provided a contemporaneous and comprehen-
sive population snapshot of S. aureus isolates from invasive disease
using an agreed sampling frame; third, it utilised modern spatial
scan statistics to identify geographical clustering; fourth, it
provided the first public domain Web-based interactive mapping
Table 3. 20 most frequent spa types and their STs among MSSA and MRSA isolated in 26 European countries.
Rank MSSA Frequency Percent
Cumulative
Percent Rank MRSA Frequency Percent
Cumulative
Percent
spa Type MLST spa Type MLST
1 t002 ST-5a, S-231a 93 4.8 4.8 1 t032 ST-22a 140 14.5 14.4
2 t084 ST-15a (ST-18) 89 4.6 9.5 2 t008 ST-8a (ST-247,
ST-250, ST-254)
120 12.4 26.8
3 t015 ST-45a 84 4.4 13.8 3 t041 ST-111a, ST-228a 72 7.4 34.2
4 t091 ST-7a 82 4.3 18.1 4 t003 (ST-5) ST-225a 71 7.3 41.6
5 t012 ST-30a 77 4.0 22.1 5 t002 ST-5a, ST-231a 62 6.4 48.1
6 t127 ST-1a 57 3.0 25.1 6 t067 ST-5a, ST-125a 50 5.2 53.3
7 t008 ST-8a (ST-247,
ST-250, ST-254)
55 2.9 27.9 7 t001 (ST-5, ST-222)
ST-228a
30 3.1 56.4
8 t021 ST-30a (ST-33, ST-55) 49 2.5 30.5 8 t037 ST-239a (ST-240),
ST-241a
27 2.8 59.2
9 t005 ST-22a (ST-23, ST-60) 42 2.2 32.7 9 t030 ST-239a (ST-246) 20 2.1 61.2
10 t026 (ST-45, ST-47) 27 1.4 34.1 10 t024 ST-8a 14 1.4 62.7
11 t065 (ST-45, ST-46) 26 1.4 35.4 11 t190 ST-8a 14 1.4 64.1
12 t160 (ST-12, ST-13) 26 1.4 36.8 12 t515 ST-22a 12 1.3 65.5
13 t056 (ST-101) 25 1.3 38.1 13 t038 ST-45a 12 1.2 66.7
14 t050 ST-45a 21 1.1 39.2 14 t022 ST-22a 11 1.1 67.8
15 t078 (ST-26) 21 1.1 40.2 15 t740 ST-45a 11 1.1 69.0
16 t164 (ST-20) 19 1.0 41.2 16 t012 ST-30a 9 0.9 69.9
17 t346 (ST-15, ST-620) 18 0.9 42.2 17 t015 ST-45a 9 0.9 70.8
18 t024 ST-8a 17 0.9 43.1 18 t044 ST-80a 9 0.9 71.8
19 t230 ST-45a 17 0.9 43.9 19 t045 ST-5a (ST-225) 8 0.8 72.6
20 t166 (ST-34) 16 0.8 44.8 20 t127 ST-1a 8 0.8 73.4
— Other — 1,062 55.2 100.0 — Other — 258 26.6 100.0
Total — — 1,923 100 — — — — 967 100 —
STs in parentheses are those associated with the spa type in the SeqNet.org Spa typing data base.
aMLST as determined by SRLs.
doi:10.1371/journal.pmed.1000215.t003
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tool for future public health research; and finally, it consolidated a
collaborative framework for the continuation of this important
European surveillance initiative.
All Member States of the European Union except Estonia,
Lithuania, Luxemburg, and Slovakia participated and variously
achieved a country-wide enrolment of diagnostic laboratories. In
the run-up to this study, a successful effort was undertaken to agree
on a single molecular typing approach to scale up the typing
capacity, and improve quality assessment, by introducing
proficiency testing for SRLs that intended to participate in
advanced S. aureus surveillance. This effort provided the basis for
the execution of a mutually agreed protocol using a standardized
sampling frame and a quality-controlled genetic typing approach
[12,15], based on the sequencing of the variable region of the S.
aureus spa gene (spa typing) [11]. Multilocus sequence typing
(MLST) was also carried out on many strains allowing most of the
prevalent spa types to be related to MLST sequence types.
However, given the scope and ambition of this investigation, it is
not surprising that the study still suffered from several operational
shortcomings.
In order to keep the amount of work manageable for the
participating SRLs, it was decided to include about 20 laboratories
that were demographically and geographically representative of
each of the participating countries. This number is arbitrary and
cannot equally represent small and large countries alike. Thus the
precision of spatial scan statistics is reduced in areas where the
density of laboratories is low. Laboratory enrolment based on
population size would provide a more appropriate sampling
strategy but would also impose a proportional and frequently
unacceptable amount of work on SRLs in large countries if
the sample size from small countries should remain meaningful.
Even medium-sized countries such as Bulgaria, Finland, Greece,
and Romania were unable to enrol the intended number of
laboratories mainly for technical and logistic reasons. Naturally,
Table 4. First, second, and third most frequent MSSA and MRSA spa types per country and their relative proportions.
Country MSSA spa Type MRSA spa Type
n 1st (%) 2nd (%) 3rd (%) n 1st (%) 2nd (%) 3rd (%)
Austria 120 t091 (8.3) t002 (6.7) t012 (5.0) 54 t190 (18.5) t041 (16.7) t001 (14.8)
Belgium 107 t002 (9.4) t209 (4.7) t012, t091, t740 (3.7) 88 t008 (29.6) t002, t038 (13.7) t740 (12.5)
Bulgaria 29 t056 (10.3) t078, t148, t156, t1346 (6.9) a 25 t030 (36.0) t037 (16.0) t010 (12.0)
Croatia 50 t050 (10.0) t005, t015, t1361 (8.0) t164 (6.4) 38 t041 (36.8) t091 (10.5) t026, t1003
(8.3)
Cyprus 9 t002 (22.2) a — 7 t012, t30
(28.6)
a —
Czech Republic 94 t015, t130 (5.3) t024, t122, t1081 (4.3) t056, t156, t491, t1231 (3.2) 51 t003 (66.7) t032 (13.7) t002 (7.8)
Denmark 108 t230 (7.4) t002, t127 (4.6) t065, t084 (3.7) 4 t024, t037
(50.0)
— —
Finland 15 t026 (13.3) a — 7 b — —
France 114 t002 (11.4) t008 (6.1) t012 (4.4) 111 t008 (48.6) t777 (7.2) t024 (5.4)
Germany 98 t008 (11.2) t084 (7.1) t015, t091 (6.1) 82 t032 (35.4) t003 (28.1) t001 (8.6)
Greece 20 t267 (15.0) t012 (10.0) a 15 t002, t044
(26.7)
t037 (20.0) a
Hungary 66 t091, t216 (10.6) t012, t084 (7.60) t002, t015, t2115 (4.7) 44 t032 (38.6) t041 (25.0) t062 (13.6)
Iceland 5 b — — 0 — — —
Ireland 85 t021 (7.1) t012 (4.7) t078, t127, t166, t382, t548 (3.6) 84 t032 (45.2) t515 (9.5) t022 (4.8)
Italy 80 t091 (10.04) t084 (8.8) t012 (7.5) 67 t041 (34.3) t008 (28.4) t001 (13.4)
Latvia 38 t435 (21.1) t015 (13.2) t313, t698 (7.9) 5 b — —
Malta 3 b — — 12 t001, t032
(30.0)
t012 (20.0) t002, t022
(10.0)
Netherlands 195 t091 (7.7) t127 (6.2) t002, t012, t084 (4.2) 9 b — —
Norway 55 t065 (9.1) t084 (9.1) t002, t015, t095 (3.7) 0 — — —
Poland 132 t127 (12.9) t084 (9.9) t015 (7.6) 47 t037 (29.81) t003, t015 (14.9) t002, t041,
t1574 (6.4)
Portugal 48 t008 (8.3) t002, t645 (6.3) t021, t127, t148, t148, t179,
t189 (4.2)
40 t032 (32.5) t002 (20.0) t535, t747,
t2357 (7.5)
Romania 25 t021, t284 (12.0) t005, t008, t450 (8.0) a 11 t030 (54.6) t127 (36.4) t015 (9.1)
Slovenia 48 t091 (20.8) t015 (10.4) t005 (8.5) 10 t041 (70.0) a —
Spain 113 t002 (12.4) t012, t067 (8.0) t015 (4.5) 91 t067 (47.3) t002 (15.4) t008 (7.7)
Sweden 195 t015 (9.2) t084 (8.2) t012 (5.7) 5 b — —
UK 71 t012, t127 (5.6) t021 (4.2) nine different types 60 t032 (61.7) t788, t1516 (3.3) a
aAll remaining spa types equally distributed.
bNo ranking, all spa types equally distributed.
doi:10.1371/journal.pmed.1000215.t004
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the number of laboratories and isolates varied between countries
and geo-demographic representation could be improved in future
investigations. The original intention was to collect equal numbers
of successive MSSA and MRSA in all laboratories during the 6-mo
sampling interval; this proved to be unrealistic, especially in
countries where MRSA levels are low. As a result, Norway and
Iceland could not provide any MRSA, whereas Sweden, Den-
mark, and the Netherlands each provided fewer than ten isolates.
Cyprus and Malta had only one participating laboratory but since
both provide the microbiological service for the whole of the
respective island population (for Cyprus, only the Republic of
Cyprus), they were entitled to submit up to 20 isolates.
Nevertheless, even taking these potential problems into account,
the simultaneous collection of 2,890 isolates from patients with
invasive S. aureus infection treated in 450 hospitals during a
6-mo study interval is unparalleled and remains unmatched by
previous investigations, which have drawn their conclusions from
convenience samples of predominantly MRSA collected by
laboratories for different clinical or biological reasons. The current
collection includes one-third MRSA and thus over-represents the
natural population of MRSA causing invasive disease, which was
22% in the European Union in 2007 [24]. All isolates were
collected from laboratories and hospitals participating in EARSS
for which estimates of the overall catchment population are
known. Thus, the present sample of hospitals catered for
approximately 22 million people, totalling 4.4% of the citizens
living in the European Union.
Despite the above limitations, the sample provides a realistic
insight into the epidemiology of S. aureus currently causing invasive
infection in Europe. The age distribution and all-cause mortality
was consistent with the expected range [29,30]. High frequencies
of invasive infections were ascertained in the very young (infants
and under 5-y-olds) and older age groups with males clearly more
at risk than females. Patients with MRSA were older than patients
with MSSA and were 2.4 times more likely to have their infection
attributed to hospital acquisition (p,0.0001). Invasive MRSA
carried a higher all-cause mortality after 14 d. This finding is most
likely confounded by a host of variables that distinguish MRSA
patients from MSSA patients in fundamental ways. All-cause
mortality was independent of spa type, indicating that this study
did not identify any single spa type that stands out with respect to
hyper-virulence or other factors that would increase the risk of
fatal outcome after 14 d. While a laboratory-based cross-sectional
study is limited in its ability to control for many of the crucial
confounders such as comorbidity and disease severity scores and
thus may not detect subtle differences in virulence properties
between different clonal lineages at the patient level, this sample
provides an unbiased estimate of the frequencies of specific spa
types that have previously been reported to cause outbreaks and
have attracted considerable public health attention. Few MRSA
isolates carried the PVL-toxin genes and this could be an
indication that many CO-MRSA were originally hospital-
acquired. Only six of the PVL-positive CO-MRSA isolates, which
made up 0.5% of the overall sample, had spa types consistent with
the CA-MRSA clones most frequently reported in Europe (t008/
ST8/SCCmecIV and t044/ST80/SCCmecIV) [31]. These values
when compared to the overall numbers of MRSA are small but
still warrant attention since PVL-positive CA-MRSA are more
Figure 3. Estimates of country-specific genetic diversity expressed as Simpson’s index of diversity of spa types (as a percentage) for
MSSA (light blue diamonds) and MRSA (dark blue diamonds) and 95% CIs (bars). Only countries for which spa type information for more
then ten MRSA isolates were available were included in this figure.
doi:10.1371/journal.pmed.1000215.g003
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commonly associated with skin and soft tissue infections and are
rarely found in blood stream infections [31] from which the
majority of the sample isolates were drawn. Livestock-associated
spa types belonging to MLST sequence type ST398 [32] made up
0.4% of the overall sample. However, none were methicillin-
resistant indicating a low rate of human systemic infections
induced by MRSA variants of this clone despite the increasing
interest and concern about such isolates by health authorities.
With the decision to utilize spa typing as a common platform to
address the geographic abundance of S. aureus clones, various
potential problems that might affect observations need to be taken
into account. First, a single sequence of approximately 280 base-
pairs under potential immune selection may be a relatively weak
indicator for the genetic background of a genome that is
approximately 10,000-times larger, even in a species such as S.
aureus that is evolving in a predominantly clonal manner.
Furthermore, convergent evolution could occur as a result of the
high mutability of the repeat region of the spa gene used in spa
typing [26,33]. Finally, spa typing on its own it may not be
sufficiently discriminatory to distinguish between MRSA isolates
given that only five spa types accounted for almost half (48.1%) of
all 967 MRSA isolates examined in this survey. The regional
clusters found in this study provide a good indication that
homoplasy is not a major problem that hinders the recognition of
clonal dissemination on a geographic scale. Moreover, when
comparing agr type, SCCmec type, toxin gene, and antibiotic
susceptibility profiles within and between different spa types, a
significant within-spa-type consistency and between-spa-type dis-
cordance supports the notion that in most cases spa typing provides
a convenient and valid marker for the major clones and clonal
lineages [34].
In order to explore the geographic distribution of different spa
types, and the genetic and phenotypic detail of isolates in the
European sample, the reader is encouraged to explore the
purpose-built interactive Web application, SRL-Maps, at http://
www.spatialepidemiology.net/srl-maps/. This application contains
Table 5. Unexpectedly frequent spa types at country level assuming a European-wide random distribution.
Country
Cluster
Number Country
spa
Type
spa
Complexa STb
n Labs
Reporting
Clustered
spa Type
n Labs
Participating
in Survey
Percent Labs
Reporting
Clustered
spa Type
n Isolates
Observed
n Isolates
Expectedc
n MRSA
among
Observed
Isolates
Percent
MRSA among
Observed
Isolates
1 Austria t190 190 8 7 18 38.9 11 0.9 10 91
2 Belgium t740 740 45 6 22 27.3 15 1.0 11 73
3 Belgium t038 740 45 8 22 36.4 12 0.8 12 100
4 Bulgaria t030 12 239 4 8 50.0 10 0.4 9 90
5 Croatia t041 1 228 7 11 63.6 14 2.2 14 100
6 Czech Republic t003 45 225 16 20 80.0 34 3.8 34 100
7 Czech Republic t130 130 — 3 20 15.0 5 0.4 5 100
8 Denmark t230 728 45 7 14 50.0 8 0.7 0 0
9 France t008 8 8 22 23 95.7 61 13.6 54 89
10 France t777 777 5 6 23 26.1 9 0.7 8 89
11 Germany t003 45 225 10 27 37.0 24 4.7 23 96
12 Germany t032 32 22 9 27 33.3 29 9.5 29 100
13 Greece t044 44 80 3 3 100.0 5 0.1 4 80
14 Hungary t062 Singleton 5 2 10 20.0 6 0.3 6 100
15 Hungary t216 Singleton 59 7 10 70.0 7 0.5 7 100
16 Ireland t032 32 22 18 22 81.8 38 8.9 38 100
17 Ireland t515 32 22 7 22 31.8 8 0.7 8 100
18 Italy t041 1 228 13 19 68.4 23 3.7 23 100
19 Italy t001 1 228 8 19 42.1 9 1.5 9 100
20 Latvia t435 435 427 4 11 36.4 8 0.2 8 100
21 Latvia t425 425 368 3 11 27.3 5 0.1 5 100
22 Poland t037 12 239 11 23 47.8 21 2.2 14 67
23 Poland t127 127 1 6 23 26.1 17 4.0 17 100
24 Romania t030 12 239 3 10 30.0 6 0.3 6 100
25 Spain t067 2 5 & 125 18 21 85.7 52 4.4 43 81
26 Spain t002 2 5 15 21 71.4 28 10.9 14 50
27 United Kingdom t032 32 22 12 15 80.0 39 6.9 27 96
Total — — — — 235 — — 504 83.4 438 87
aspa complexes group spa types that differ by only a single evolutionary event (single indel or nucleotide polymorphism) into the same complex.
bAs determined by SRLs.
cAverage number of isolates with this spa type expected in country after 10,000 simulations on the basis of European-wide cumulative frequency.
doi:10.1371/journal.pmed.1000215.t005
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the public domain data made available to the scientific and public
health community by all SRLs that participated in the study. It
also illustrates the potential of such a communication platform.
The underlying database is fully searchable and the map-based
application is a template for the future addition of further
epidemiological and biological information. We believe that this
approach to spatial epidemiology will become a rich resource for
future enquiry into the population dynamics of infectious agents
and their evolution.
In conclusion we provide evidence that the major MRSA clones
in Europe occur predominantly in geographical clusters. This also
indicates that MRSA, rather than spreading freely in the
community, diffuses through regional health care networks. This
important finding suggests that control efforts aimed at interrupting
the spread within and between health care institutions may not only
be feasible but ultimately successful and should therefore be strongly
encouraged. We also showed that an international surveillance
network sharing decentralised typing results on a Web-based
platform can provide crucial information for clinicians, diagnostic
microbiologists, and infection control teams on the dynamics of
S. aureus spread, and especially the spread of MRSA isolates, to
provide early warning of emerging strains, cross-border spread, and
importation by travel.
Supporting Information
Text S1 Affiliations and contact information of the Staphylococcus
aureus Reference Laboratory Working Group members.
Found at: doi:10.1371/journal.pmed.1000215.s001 (0.16 MB
DOC)
Table 6. Regional clusters of spa types.
Regional
Cluster
Number
spa
Type
spa
Complexa STb Window Centre
Window
Radius
(km)
Countries
reporting Clustered
spa Type within
Window
n Isolates
Observed
n Isolates
Expectedc
Log
Likelihood
Ratio
n MRSA
among
Observed
Isolates
Percent
MRSA among
Observed
Isolates
1 t067 2 5 & 125 Alicante, Spain 716 ES, FR 55 4.7 126.9 46 84
2 t041 1 228 Split, Croatia 522 AT, HR, HU, SI, IT 59 10.6 84.76 59 100
3 t032 32 22 Belfast, Northern
Ireland (UK)
596 IE, UK 77 15.9 84.74 75 97
4 t003 45 225 Leipzig, Germany 386 CZ, DE, PL 58 10.0 82.26 54 93
5 t008 8 8 Perpignan, France 931 AT, BE, DE, ES, FR,
HR, PT, SI
119 45.5 72.96 105 88
6 t740 740 45 Goes, Netherlands 81 BE, NL 15 0.6 50.36 11 73
7 t030 12 239 Pleven, Bulgaria 331 BG, RO 16 0.7 45.24 15 94
8 t037 12 239 Plock, Poland 330 PL 21 2.2 36.02 18 86
9 t038 740 45 Wilrijk, Belgium 92 BE 12 0.8 32.71 12 100
10 t190 190 8 St Po¨lten, Austria 56 AT 10 0.3 29.63 9 90
11 t001 1 228 Sibenik, Croatia 885 AT, DE, HU, IT, MT 29 10.2 27.55 29 100
12 t435 435 427 Daugavpils, Latvia 189 LV 8 0.2 25.82 0 0
13 t425 239 368 Riga, Latvia 0 LV 5 0.1 22.76 5 100
14 t127 127 1 Inowroclaw, Poland 131 PL 12 0.9 22.65 0 0
15 t032 32 22 Berlin, Germany 128 DE 19 3.2 22.2 19 100
16 t015 15 45 Lomza, Poland 581 CZ, LV, PL 35 11 20.72 7 20
17 t091 91 7 Ried, Austria 771 AT, BE, CZ, DE, FR, HR,
HU, IT, NL, PL, SI
71 42.8 20.68 4 6
18 t777 777 5 Laval, France 277 FR 7 0.3 20.61 7 100
19 t081 78 25 Mako´w
Mazowiecki, Poland
0 PL 4 0.0 19.37 3 75
20 t515 32 22 Mullingar, Ireland 196 IE, Northern Ireland
(UK)
9 0.7 18.94 9 100
21 t002 2 5, 231 Coimbra, Portugal 484 ES, PT 33 10.6 18.37 20 61
22 t230 728 45 Hilleroed, Denmark 235 DE, DK, SE 11 1.4 17.19 0 0
23 t044 44 80 Nicosia, Cyprus 916 GR, CY 6 0.2 17.09 6 100
24 t2054 8 8 St Mande, France 226 BE, FR4 5 0.2 16.64 3 60
25 t062 singleton 5 Szolnok, Hungary 145 HU 6 0.3 15.24 6 100
Total — — — — 368 (mean) 339 702 173.1 — 522 74
Analyses were performed for spa types with five or more isolates during the study period.
aspa complexes group spa types that differ by only a single evolutionary event (single indel or nucleotide polymorphism) into the same complex.
bAs determined by SRLs.
cAverage number of isolates with this spa type expected in window after 10,000 simulations on the basis of European-wide cumulative frequency.
AT, Austria; BE, Belgium; BG, Bulgaria; CY, Cyprus; CZ, Czech Republic; DE, Germany; DK, Denmark; ES, Spain; FI, Finland; FR, France; GR, Greece; HR, Croatia; HU, Hungary;
IE, Ireland; IT, Italy; LV, Latvia; MT, Malta; NL, Netherlands; PL, Poland; PT, Portugal; RO, Romania; SE, Sweden, SI, Slovenia; UK, United Kingdom.
doi:10.1371/journal.pmed.1000215.t006
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Text S2 Author contributions of the Staphylococcus aureus
Reference Laboratory Working Group members.
Found at: doi:10.1371/journal.pmed.1000215.s002 (0.13 MB
DOC)
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Editors’ Summary
Background. The bacterium Staphylococcus aureus lives on
the skin and in the nose of about a third of healthy people.
Although S. aureus usually coexists peacefully with its human
carriers, it is also an important disease-causing organism or
pathogen. If it enters the body through a cut or during a
surgical procedure, S. aureus can cause minor infections such
as pimples and boils or more serious, life-threatening
infections such as blood poisoning and pneumonia. Minor
S. aureus infections can be treated without antibiotics—by
draining a boil, for example. Invasive infections are usually
treated with antibiotics. Unfortunately, many of the S. aureus
clones (groups of bacteria that are all genetically related and
descended from a single, common ancestor) that are now
circulating are resistant to methicillin and several other
antibiotics. Invasive methicillin-resistant S. aureus (MRSA)
infections are a particular problem in hospitals and other
health care facilities (so-called hospital-acquired MRSA
infections), but they can also occur in otherwise healthy
people who have not been admitted to a hospital
(community-acquired MRSA infections).
Why Was This Study Done? The severity and outcome of
an S. aureus infection in an individual depends in part on the
ability of the bacterial clone with which the individual is
infected to cause disease—the clone’s ‘‘virulence.’’ Public-
health officials and infectious disease experts would like to
know the geographic distribution of the virulent S. aureus
clones that cause invasive infections, because this
information should help them understand how these
pathogens spread and thus how to control them. Different
clones of S. aureus can be distinguished by ‘‘molecular
typing,’’ the determination of clone-specific sequences of
nucleotides in variable regions of the bacterial genome (the
bacterium’s blueprint; genomes consist of DNA, long chains
of nucleotides). In this study, the researchers use molecular
typing to map the geographic distribution of MRSA and
methicillin-sensitive S. aureus (MSSA) clones causing invasive
infections in Europe; a MRSA clone emerges when an MSSA
clone acquires antibiotic resistance from another type of
bacteria so it is useful to understand the geographic
distribution of both MRSA and MSSA.
What Did the Researchers Do and Find? Between
September 2006 and February 2007, 357 laboratories serving
450 hospitals in 26 European countries collected almost
3,000 MRSA and MSSA isolates from patients with invasive S.
aureus infections. The isolates were sent to the relevant
national staphylococcal reference laboratory (SRL) where
they were characterized by quality-controlled sequence
typing of the variable region of a staphylococcal gene
called spa (spa typing). The spa typing data were entered
into a central database and then analyzed by a public,
purpose-built Web-based mapping tool (SRL-Maps), which
provides interactive access and easy-to-understand
illustrations of the geographical distribution of S. aureus
clones. Using this mapping tool, the researchers found that
there was a wide geographical distribution of spa types
across Europe with some types being common in all
European countries. MSSA isolates were more diverse than
MRSA isolates and the genetic diversity (variability) of MRSA
differed considerably between countries. Most importantly,
major MRSA spa types occurred in distinct geographical
clusters.
What Do These Findings Mean? These findings provide
the first representative snapshot of the genetic population
structure of S. aureus across Europe. Because the researchers
used spa typing, which analyzes only a small region of one
gene, and characterized only 3,000 isolates, analysis of other
parts of the S. aureus genome in more isolates is now needed
to build a complete portrait of the geographical abundance
of the S. aureus clones that cause invasive infections in
Europe. However, the finding that MRSA spa types occur
mainly in geographical clusters has important implications
for the control of MRSA, because it indicates that a limited
number of clones are spreading within health care networks,
which means that MRSA is mainly spread by patients who
are repeatedly admitted to different hospitals. Control efforts
aimed at interrupting this spread within and between health
care institutions may be feasible and ultimately successful,
suggest the researchers, and should be strongly encouraged.
In addition, this study shows how, by sharing typing results
on a Web-based platform, an international surveillance
network can provide clinicians and infection control teams
with crucial information about the dynamics of pathogens
such as S. aureus, including early warnings about emerging
virulent clones.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000215.
N This study is further discussed in a PLoS Medicine
Perspective by Franklin D. Lowy
N The UK Health Protection Agency provides information
about Staphylococcus aureus
N The UK National Health Service Choices Web site has pages
on staphylococcal infections and on MRSA
N The US National Institute of Allergy and Infectious Disease
has information about MRSA
N The US Centers for Disease Control and Infection provides
information about MRSA for the public and professionals
N MedlinePlus provides links to further resources on
staphylococcal infections and on MRSA (in English and
Spanish)
N SRL-Maps can be freely accessed
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